Company beats expectations and sees strong growth
- AstraZeneca shares rose 4.2% after raising full-year guidance
- Core earnings per share expected to increase by a low double-digit percentage
- Total revenue excluding Covid-19 medicines expected to increase by a low-teens percentage
- Net profit for the quarter was $1.37 billion
Shares of AstraZeneca surged 4.2% after the company raised its full-year guidance for core earnings per share and total revenue. The pharmaceutical giant exceeded expectations for the third quarter, with core earnings per share rising 9% and revenue increasing by 6% at constant-exchange rates. AstraZeneca now expects core earnings per share to increase by a low double-digit percentage, while total revenue excluding Covid-19 medicines is expected to grow by a low-teens percentage. Net profit for the quarter was $1.37 billion. Overall, AstraZeneca’s strong performance and increased guidance indicate positive growth for the company.
Factuality Level: 8
Factuality Justification: The article provides specific information about AstraZeneca’s financial performance, including its increase in core earnings per share and total revenue. The information is supported by numbers and comparisons to previous guidance and consensus estimates. There is no obvious bias or opinion presented in the article.
Noise Level: 6
Noise Justification: The article provides information on AstraZeneca’s financial performance and revised guidance for the year. It includes details on core earnings per share, total revenue, and net profit. The article also mentions the company’s stock performance. However, it lacks analysis or insights into the implications of these numbers and does not provide any actionable information for the reader.
Financial Relevance: Yes
Financial Markets Impacted: Shares of AstraZeneca
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article pertains to financial topics as it discusses AstraZeneca’s financial performance and its impact on the company’s shares. There is no mention of an extreme event.
Public Companies: AstraZeneca (AZN)
Key People:
Reported publicly:
www.marketwatch.com 
